Henagliflozin may help kidney cells remove damaged mitochondria by activating energy sensors to slow diabetic kidney disease
Updated
Abstract
Diabetic Kidney Disease (DKD) is a leading cause of end-stage kidney disease.
- Henagliflozin (Hen), an SGLT2 inhibitor, is associated with significant protective effects on kidney function.
- The specific mechanisms through which Henagliflozin provides renoprotection are not yet fully understood.
- Further investigation is needed to clarify how Henagliflozin impacts kidney health in the context of DKD.
Simplified